1642333-05-8

Basic information

• Product Name: docosanedioic acid mono-tert-butyl ester
• CAS NO: 1642333-05-8
• Molecular Weight: 426.681
• Mol File: 1642333-05-8.mol

Chemical Properties

• CAS DataBase Reference: docosanedioic acid mono-tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: docosanedioic acid mono-tert-butyl ester(1642333-05-8)
• EPA Substance Registry System: docosanedioic acid mono-tert-butyl ester(1642333-05-8)

Safety Data

• Hazardous Substances Data: 1642333-05-8(Hazardous Substances Data)

Usage

Uses

Used in Chemical Production:
Docosanedioic acid mono-tert-butyl ester is used as an intermediate in the production of various other chemicals for its ability to facilitate chemical reactions and syntheses.
Used as a Plasticizer in Polymers:
In the polymer industry, docosanedioic acid mono-tert-butyl ester is used as a plasticizer to increase the flexibility and workability of certain polymers, enhancing their performance characteristics.
Used in Lubricant Production:
docosanedioic acid mono-tert-butyl ester is utilized as a raw material in the production of lubricants, where its chemical properties contribute to the development of high-quality lubricating products.
Used in Synthetic Resin Manufacturing:
Docosanedioic acid mono-tert-butyl ester is employed in the manufacturing of synthetic resins, where it plays a role in the formation of durable and versatile resinous materials.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, docosanedioic acid mono-tert-butyl ester is used in certain drug delivery systems, potentially improving the efficacy and targeted delivery of pharmaceuticals.
Used in Fuel Additives:
docosanedioic acid mono-tert-butyl ester has potential applications in the field of fuel additives, where it may contribute to enhancing fuel performance or reducing environmental impact.
Used in Coatings and Adhesives Formulation:
Docosanedioic acid mono-tert-butyl ester is also found in the formulation of coatings and adhesives, where it can improve the bonding properties and durability of these products.

Upstream product

• 505-56-6 docosanedioic acid 
• 75-65-0 tert-butyl alcohol 
• 1642333-07-0 20-bromo-icosanoic acid tert-butyl ester 
• 683239-16-9 eicosanedioic acid mono(1,1-dimethylethyl)ester 

Relevant articles and documents

EXENATIDE MODIFIER AND USE THEREOF

Disclosed are an exenatide modifier for connecting the exenatide to a fatty chain with a carboxy in the terminus thereof by means of a hydrophilic connecting arm, and a use thereof in preparing drugs serving as a GLP-1 receptor agonist; a use in preparing drugs for preventing and/or treating diseases and/or symptoms associated with a low GLP-1 receptor activity; a use in preparing drugs for diseases and/or symptoms associated with glycometabolism; a use in preparing drugs for diabetes; a use in preparing drugs for fatty liver disease, and a use in preparing drugs for losing weight.

GLP-1 Derivatives and Uses Thereof

The invention relates to a derivative of a GLP-1 analogue, optionally C-terminally extended, which derivative comprises a first and a second protracting moiety in the form of a C20 or C22 diacid radical, a bis-amino branched linker, and a first and a second further linker each comprising an OEG-like linker element; wherein these elements are interconnected via amide bonds and attached to a Lys residue of the GLP-1 analogue. The invention also relates to intermediate products in the form of novel GLP-1 analogues incorporated in the derivatives of the invention, as well pharmaceutical compositions and medical uses of the derivatives. The derivatives have very long half-lives while maintaining a satisfactory potency, which makes them potentially suitable for once-monthly administration.

DERIVATIVES OF GLP-1 LIKE PEPTIDES, AND USES THEREOF

The invention relates to derivatives of GLP-1 like peptides which are C-terminally extended analogues of native GLP-1. The derivatives comprise two side chains, one at a position corresponding to position 42, and one at a position corresponding to position 18, 23, 27, 31, 36, or 38, wherein both positions are when compared to GLP-1(7-37). The side chains comprise a C19, C20, or C22 diacid protracting moiety and optionally a linker. The invention also relates to intermediate products in the form of novel GLP-1 analogues incorporated in the derivatives of the invention, as well as pharmaceutical compositions and medical uses of the derivatives. The derivatives have very long half-lives while maintaining a satisfactory potency, which makes them potentially suitable for once-monthly administration.